Month: June 2020

CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming virtual investor conferences:  Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 3:00 p.m. E.T.BofA Securities Napa Biopharma Conference on Wednesday, June 24, 2020 at 12:30 p.m. E.T.The presentations will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.About Sarepta TherapeuticsAt Sarepta,...

TORONTO, June 02, 2020 (GLOBE NEWSWIRE) — The Board of Directors of Constellation Software Inc. (“Constellation”) (TSX: CSU) announced today the appointment of Donna Parr, Andrew Pastor, Barry Symons and John Billowits to Constellation’s Board of Directors.Donna Parr has significant experience in venture and private equity investing and corporate finance working for Canadian Medical Discoveries Fund, Ontario Municipal Employees Retirement System, Canada Pension Plan, and several other institutional investors.  Ms. Parr has served on 35 boards of private companies primarily on behalf of institutional investors and several as an Independent Corporate Director, including a term as a director of Constellation from 1995 to 2003.  Ms. Parr is currently the President of Crimson Capital, and a Director of the Centurion Financial Trust....

VANCOUVER, British Columbia, June 02, 2020 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) (“SHARC” or the “Company”) has previously announced on April 24, 2020 and May 15, 2020 that the Company will be relying on relief granted by the British Columbia Securities Commission (“BCSC”) under BC Instrument 51-525 (“BCI 51-525“) for temporary exemption from certain continuous disclosure requirements due to the challenges created by COVID-19. A copy of the temporary exemption granted by the BCSC in response to the COVID-19 Pandemic can be found here: BC Instrument 51-515.The Company expects to file the following annual filings by June 5, 2020:Audited Annual Financial Statements for the year ended December 31, 2019Management Discussion and Analysis for the year ended December...

TORONTO, June 02, 2020 (GLOBE NEWSWIRE) — Wesdome Gold Mines Ltd. (TSX: WDO) (the “Company”) announces the results of the Company’s annual general meeting of shareholders (the “Meeting”) held by way of live webcast earlier today. A replay of the Meeting is available on the Company’s website.A total of 71,804,870 common shares were represented at the Meeting, representing 51.86% of the total issued and outstanding common shares of the Company.All matters presented for shareholder approval at the Meeting were approved, as follows:Election of DirectorsThe following seven individuals were elected as directors of the Company, until the next annual meeting of shareholders, as set out in the table below:Re-Appointment of AuditorsBased on proxies received and votes cast by show of hands during the Meeting, Grant Thornton LLP, Chartered...

LYON, France and CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil BEYEN, Chief Executive Officer, will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 08:30 am ET.Presentation Details:Event: Jefferies Virtual Healthcare Conference – Q&A sessionDate: Thursday, June 4, 2020Time: 08:30am to 08:55am ETAbout ERYTECH and eryaspaseERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology...

Montrouge, France, June 2, 2020DBV Technologies To Present at the Goldman Sachs 41stAnnual Global Healthcare ConferenceDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will present at the Goldman Sachs 41st Annual Global Healthcare Conference, on Tuesday, June 9, 2020, at 1:20pm EST.A live webcast of the virtual presentation will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay will be available on the DBV website for 30 days following the event.About DBV Technologies DBV Technologies is developing Viaskin®, an investigational proprietary technology platform with broad potential applications in immunotherapy....

Montrouge, France, le 2 juin (22 h 30 CEST) 2020DBV Technologies participera à la 41èmeGoldman Sachs Annual Global Healthcare ConferenceDBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT), une société biopharmaceutique de stade clinique, a annoncé aujourd’hui que Daniel Tassé, Directeur Général de la société, interviendra lors de la 41ème Goldman Sachs Annual Global Healthcare Conference, le mardi 9 juin 2020, à 13h20 (heure locale) / 19h20 (heure de Paris).Une retransmission en direct de sa présentation sera disponible dans la section Investisseurs & Presse du site internet de la société : https://www.dbvtechnologies.com/investor-relations/. Une rediffusion de la présentation sera également disponible sur le site internet de DBV après l’événement.À propos de DBV TechnologiesDBV Technologies développe...

BALA CYNWYD, Pa., June 02, 2020 (GLOBE NEWSWIRE) — Private markets asset management firm Hamilton Lane Incorporated (NASDAQ: HLNE) (“Hamilton Lane”) today announced that it has commenced an underwritten public offering of 2,995,757 shares of Class A common stock, in the aggregate, to be sold by Hamilton Lane and three selling stockholders, subject to market and other conditions. Hamilton Lane intends to use the proceeds from the sale of its shares to settle in cash exchanges of membership units in Hamilton Lane Advisors, L.L.C. held by certain of its members.  Hamilton Lane will not receive any proceeds from the sale of shares by the selling stockholders.J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are acting as joint book-running managers and underwriters for the offering.The offering is being made pursuant to an...

SÃO PAULO, Brazil, June 02, 2020 (GLOBE NEWSWIRE) — Arco Platform Limited, or Arco (Nasdaq: ARCE), announced today the commencement of an underwritten public offering of 5,563,203 Class A common shares to be offered by General Atlantic Arco (Bermuda), L.P and Alfaco Holding Inc.Arco will not receive any proceeds from the sale of Class A common shares by the Selling Shareholders. Neither Arco nor any other of its other shareholders, including its founding shareholders and members of management, are selling Class A common shares in this offering.Goldman Sachs & Co. LLC and Itau BBA USA Securities, Inc. are acting as underwriters in this public offering.The offering is being made only by means of a prospectus and related prospectus supplement forming part of a shelf registration statement on Form F-3 that was previously filed...

Media ReleaseThe U.S. FDA has notified Novartis that the agency has extended its review of the sBLA for subcutaneous ofatumumab in RMSRegulatory action in the U.S. now anticipated in September 2020Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (U.S. FDA) has notified Novartis that the agency has extended its review of the supplemental Biologics License Application (sBLA) for subcutaneous ofatumumab for the treatment of relapsing forms of multiple sclerosis (RMS) in adults. Regulatory action in the U.S. is now anticipated in September 2020. Ofatumumab is being developed and marketed worldwide by Novartis under a license agreement between Genmab and Novartis Pharma AG.“As our partner Novartis works with the U.S. FDA to continue the review for subcutaneous ofatumumab in relapsing multiple sclerosis,...